- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06054659
CGM and DFU Healing Post-discharge
A Randomized Controlled Open-label Study Comparing the Use of Real-time Continuous Glucose Monitoring (Rt-CGM) to Point of Care Testing (POCT) for Glycemic Monitoring in Patients Post-hospitalization for Diabetic Foot Ulcers.
The purpose of this study is to look at the benefits of using a Continuous Glucose Monitoring (CGM) system compared with standard-of-care testing for patients with diabetes type 2 and diabetic foot ulcers (DFU) and how this will improve wound healing.
The CGM system allows medical staff and patients with diabetes to monitor and make treatment decisions to improve glucose control, without the need for performing fingersticks. Hence, the use of CGM will decrease the painful and burdensome task of performing finger sticks several times per day and may prevent low blood glucose in patients with diabetes.
Study Overview
Status
Detailed Description
The goals of this study are to compare differences in patients with diabetic foot ulcer (DFU) wound healing using continuous glucose monitor (CGM) and point of care testing (POCT) at 16 weeks post-hospital discharge. The study is important to support the limited data available to optimize glycemic control DFU healing and the use of CGM. Patients with type 2 diabetes (T2D) and HbA1c > 8.5% admitted to general medicine and surgery services with diabetic foot ulcers will be approached for study participation.
After completing the informed consent process, patients will be randomized 1:1 to glucose monitoring with real-time CGM (rt-CGM) or POCT. Before discharge, participants in the rt-CGM group will have CGM applied by the research team with instructions on how to monitor blood glucose (BG) with the CGM device. Participants enrolled in the POCT group will have the application of a blinded CGM that will monitor glycemic control, but results will not be visible to the participant, clinical team, or research providers. Participants will receive standard diabetes education. Participants will be scheduled for research visits at 4, 8, 12, and 16 weeks. CGM sensors will be provided at these visits with a review of application, monitoring, and removal. Subjects in both groups will not receive specific guidelines on medication or other interventions. At the end of the 16-week study period, an assessment of final wound outcomes will be made by either the podiatry or infectious diseases collaborators (one of whom will have already been following the patient clinically) during one of the routine clinical visits. Photos of the ulcer site will be taken at the 16-week study visit, and the outcome will be reported by the treating wound care provider and adjudicated by a member of the study team who is blinded to the patient's clinical information and intervention arm. Participants will complete surveys to assess patient-reported outcomes relating to depression, CGM satisfaction, and self-efficacy.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maya Fayfman, MD
- Phone Number: 404-778-1664
- Email: maya.fayfman@emory.edu
Study Contact Backup
- Name: Gerardo Blanco, MD
- Phone Number: 404-778-1710
- Email: gjblanc@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
- Recruiting
- Grady Health System
-
Contact:
- Gerardo Blanco, MD
- Phone Number: 404-778-1710
- Email: gjblanc@emory.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults aged 18 and over with type 2 diabetes admitted to general medical and surgical services with diabetic foot ulceration with or without infection (cellulitis or osteomyelitis)
- HbA1c >= 8.5% at time of enrollment
- Treatment of diabetic foot ulcer with medical management and/or debridement
- Wound, Ischemia, foot Infection (WIfI) score of 1-3
- Duration of DFU less than 1 year
- Able and willing to use continuous glucose monitoring technology independently or with the assistance of a close relative or caretaker
Exclusion Criteria:
- Age < 18 years
- A WIfI score of 4 denoting very high risk for major amputation (above or below the knee) and very low odds of healing within 12 months
- Any amputation (major or minor) in the limb with a DFU during hospitalization
- Patients with type 1 diabetes
- Clinically significant peripheral arterial disease where revascularization is indicated
- Inability to participate in the informed consent process for any reason
- Female subjects who are pregnant or breastfeeding at the time of enrollment in the study
- Subjects using CGM technology prior to admission
- Subjects unwilling to wear a CGM device and/or monitor blood glucose with FBG
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Real time - Continuous glucose monitoring
Participants will wear a CGM sensor in the abdomen or arm placed by a study team prior to hospital discharge.
Participants will have instructions on how to monitor BG with the CGM device and will use their own glucometer and do fingersticks as needed including for CGM calibration.
|
Participants randomized to rt-CGM will have CGM placed prior to hospital discharge.
They will also receive teaching from the research team on the proper use of their CGM sensor and reader.
The study team will CGM devices but subjects may use their own glucometer for FBG testing as needed including for CGM calibration.
Other Names:
Participants will use their own glucometer for FBG testing as advised by their treating provider (usually primary care or diabetes doctor).
Other Names:
Participants will receive standard-of-care diabetes education with a certified diabetes educator (CDE) prior to discharge (with the approval of the treating inpatient team).
|
Active Comparator: Fingerstick blood glucose (FBG) monitoring
Participants randomized to this group will monitor blood glucose by performing fingersticks, they will also have the application of CGM but will not be given the receiver to allow for self-monitoring.
CGM will only be applied by the research team for monitoring over a 14-day interval at baseline, week 4, week 8, and week 12. Blinding will continue throughout the study.
This group will receive training only in home BG monitoring with FBG.
|
Participants will use their own glucometer for FBG testing as advised by their treating provider (usually primary care or diabetes doctor).
Other Names:
Participants will receive standard-of-care diabetes education with a certified diabetes educator (CDE) prior to discharge (with the approval of the treating inpatient team).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DFU wound healing rates
Time Frame: up to 16 weeks post-discharge
|
Number of participants with DFU wound healing rates in both groups
|
up to 16 weeks post-discharge
|
Time to DFU healing
Time Frame: up to 16 weeks post-discharge
|
DFU healing will be assessed by two investigators blinded to the study intervention
|
up to 16 weeks post-discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient reported World Health Organization Well-Being Index
Time Frame: Baseline and 16 weeks post-discharge
|
The raw score is calculated by totaling the figures of the five answers.
The raw score ranges from 0 to 25, with 0 representing the worst possible and 25 representing the best possible quality of life.
To obtain a percentage score ranging from 0 to 100, the raw score is multiplied by 4. A percentage score of 0 represents the worst possible, whereas a score of 100 represents the best possible quality of life.
A score below 13 indicates poor well-being and is an indication for testing for depression.
In order to monitor possible changes in wellbeing, the percentage score is used.
A 10% difference indicates a significant change.
|
Baseline and 16 weeks post-discharge
|
Change in patient reported diabetes distress scores (DDS)
Time Frame: Baseline and 16 weeks post-discharge
|
The DDS yields a total diabetes distress score plus 4 subscale scores, each addressing a different kind of distress.
To score, simply sum the patient's responses to the appropriate items and divide by the number of items in that scale.
Current research suggests that a mean item score of 2.0 - 2.9 should be considered 'moderate distress,' and a mean item score > 3.0 should be considered 'high distress.'
Current research also indicates that associations between DDS scores and behavioral management and biological variables (e.g., A1C) occur with DDS scores of > 2.0.
Clinicians may consider moderate or high distress worthy of clinical attention, depending on the clinical context.
|
Baseline and 16 weeks post-discharge
|
Change in patient reported CGM satisfaction (CGM-SAT)
Time Frame: Baseline and 16 weeks post-discharge
|
CGM-SAT: This 44-item questionnaire was designed to measure the impact of using CGM on diabetes management and family relationships and on satisfaction with the emotional, behavioral, and cognitive effects of CGM use.
Participants rate their agreement or disagreement on a 5-point Likert scale (1 = strongly agree; 5 = strongly disagree) with each of 44 potential positive or negative effects of the use of the rated CGM device.
Higher scores reflect a more favorable impact of, and satisfaction with, CGM use.
|
Baseline and 16 weeks post-discharge
|
Change in patient reported Glucose Monitoring Survey (GMS)
Time Frame: Baseline and 16 weeks post-discharge
|
GMS is a 22-item scale constructed for this trial that quantifies respondents' satisfaction with and therapeutic impact of the glucose monitoring systems that they were currently using (SMBG alone or with CGM).
The 22 two-part items ask the respondent to evaluate "Is this a problem now?" and then "How has it changed in the past 6 months?"
Response options for the "Problem" questions range from 1 = "a lot" to 4 = "not at all," while those for the "Change" questions range from 1 = "worse" to 3 = "better."
Higher scores on the "Problem" questions indicate more positive views of the rated glucose monitoring system.
Higher scores on the "Change" questions indicate greater perceived improvement.
|
Baseline and 16 weeks post-discharge
|
Frequency of medication adjustments
Time Frame: Up to 16 weeks post discharge
|
The frequency of medication adjustments including initiation of new non-insulin-based therapy, basal and/or prandial insulin therapy, and/or dose adjustments will be documented during study participation.
|
Up to 16 weeks post discharge
|
Glycemic variability
Time Frame: Baseline and 16 weeks post-discharge
|
Glycemic variability (GV) will be assessed by coefficient of variation (CV) and standard deviation from baseline and 12 weeks.
Based on the published literature, the 2017 international consensus statement on the use of CGM suggested that 'stable glucose levels are defined as a CV <36% and unstable glucose levels are defined as CV ≥36%
|
Baseline and 16 weeks post-discharge
|
Relationship of time in range (TIR) and likelihood of healing
Time Frame: Up to 16 weeks post discharge
|
Time in Range (%TIR) is the percentage of time that a person spends with their blood glucose levels in a target range (70-180 mg/dL).
A time-to-event (TTE) analysis will be conducted with the primary outcome based on time in range (%TIR) stratification among all study subjects.
The stratification will be done for groups where %TIR ≥ 50 and %TIR < 50%.
|
Up to 16 weeks post discharge
|
Relationship of time below range (%TBR) and likelihood of healing
Time Frame: Up to 16 weeks post discharge
|
Healing rate compared to each %TBR level 1 (54 - < 70 mg/dL); %TBR Level 2 (BG<54 mg/dL)
|
Up to 16 weeks post discharge
|
Relationship of time above range (%TAR) and likelihood of healing
Time Frame: Up to 16 weeks post discharge
|
Healing rate compared to each %TAR level 1 (BG >180 - 250 mg/dL); %TAR level 2 (BG >250 mg/dL)
|
Up to 16 weeks post discharge
|
Relationship of glycemic variability and the likelihood of healing
Time Frame: Up to 16 weeks post discharge
|
Healing rate compared to GV
|
Up to 16 weeks post discharge
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maya Fayfman, MD, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00006202
- R03DK137007-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States, Canada
-
HealthpointCompleted
Clinical Trials on Real Time Continuous Glucose Monitoring (rt-CGM)
-
Medical Research Foundation, The NetherlandsMedtronicCompletedGlucose Metabolism Disorders | Perioperative CareNetherlands
-
University Hospital, ToursCompleted
-
Sheba Medical CenterUnknownDiabetes MellitusIsrael
-
Peking University Third HospitalBeijing Municipal Health CommissionRecruitingPregnancy Related | Pregnancy Outcome | Time in Range | Type2diabetes | Continuous Glucose MonitoringChina
-
Medical Research Foundation, The NetherlandsCompletedDiabetes Mellitus, Type 1Netherlands
-
Manchester University NHS Foundation TrustDexCom, Inc.CompletedDiabetes Mellitus, Type 1United Kingdom
-
University Hospital, AntwerpCompleted
-
Charles University, Czech RepublicUnknown
-
West China HospitalCompletedFeasibility | Safety | Continuous Glucose Monitoring System | AccuracyChina
-
Charles University, Czech RepublicUnknownDiabetes Mellitus, Type 1Czechia